BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidate
read at Endpoints ↗Negative
BeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025.
Despite the expansion, the company announced it will discontinue five cancer programs and a Phase 2 autoimmune candidate as part of a portfolio review.
The move reflects a strategic refocus, aiming to allocate resources toward the most promising assets while reducing the risk of an over-extended pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BeOne culls five cancer programs and an autoimmune Phase 2”
read at Endpoints ↗81 words · retrieved May 6
comments(0)
5-min edit window · permanent after that